Chromosomes
Chromosomes

GlaxoSmithKline Boosts Its Cancer Drug Pipeline

British drug giant GlaxoSmithKline (NYSE: GSK) has entered a new oncology arena with its acquisition of Tesaro Inc. (NASDAQ: TSRO) for approximately $5.1 billion. Tesaro is a commercial-stage biopharmaceutical company whose major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved for use in ovarian cancer. Specifically, it is in […]